Jefferies downgrades Symrise stock on demand concerns, cuts price target

Jefferies downgraded Symrise AG (SY1G:GR) to Underperform with a price target of EUR90, citing concerns about staples demand and a potential slowdown in volumes despite the company's historically low price volatility (beta of 0.51). The downgrade follows Symrise's Q1 sales of €1,317 million, slightly below consensus, though organic growth exceeded expectations at 4.2%; the firm also considers strategic options for its Terpene business to improve margins, and reaffirmed its long-term growth and EBITDA margin targets, which initially sparked a positive market reaction.

Analysis

Jefferies has downgraded Symrise AG to Underperform from Hold, reducing the price target to EUR90.00 from EUR100.00, primarily due to concerns regarding staples demand within the ingredients sector and a modest inventory build indicating potentially weaker volumes in the second half of the year. While acknowledging Symrise's relative resilience due to its exposure to private label and smaller customers, and its historically low price volatility (beta of 0.51), Jefferies expressed skepticism about the company's topline outlook, which relies on stronger H2 performance during the initial year of its new CEO's strategic implementation. This contrasts with InvestingPro data highlighting Symrise's 'GREAT' financial health score and an 18-year history of consistent dividend payments. Jefferies has also lowered its mid-term EBITDA forecast for Symrise by 4%, placing it 3% below consensus, and has factored lower long-term margins into its discounted cash flow model. Despite these concerns, Symrise reported first-quarter sales of €1,317 million, slightly under the consensus of €1,329 million, but achieved stronger-than-expected organic growth of 4.2%, surpassing the 3.5% forecast. The Q1 EBITDA margin was approximately 21%, aligning closely with the 21.1% consensus. Furthermore, Symrise is exploring strategic options for its Terpene business, which contributes over €100 million in revenue at near-zero margins; optimizing this segment could enhance overall margins by up to 40 basis points. The company reaffirmed its long-term targets of 5-7% organic growth and an EBITDA margin around 21%, developments that, along with strong Q1 organic growth, initially received a positive market reaction.

Key Decisions for Investors

• Investors should closely monitor Symrise's volume development in the second half of the year, given Jefferies' concerns about weaker demand and inventory build-up.
• The execution of the new CEO's strategy and the progress on the strategic review of the Terpene business are key catalysts to watch, as successful optimization could significantly improve margins and support long-term growth targets.
• Despite the downgrade, consider the company's strong underlying financial health, consistent dividend record, and recent outperformance in organic growth when evaluating positions, balancing these against the highlighted sector headwinds and analyst skepticism.